NCT06024408View on ClinicalTrials.gov

A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis (NASH)Genetic Risk Factor
Interventions
DRUG

ALN-PNP

Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

DRUG

Placebo

Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)

Trial Locations (5)

13496

CHA Bundang Medical Center, Seongnam-si

28644

Chungbuk National University Hospital, Cheongju-si

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06024408 - A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor | Biotech Hunter | Biotech Hunter